Pharmaceutical

FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea

Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.

Dec 25, 2024 - 06:00
FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea
Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.
Read the original article

Tags:

Previous Article

AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment

Next Article

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Moderna CEO made $398 million in 2022, but still pledges to give most to charity

STAT+: Moderna CEO made $398 million in 2022, but still...

Mar 19, 2023

Evotec partners with Crohn’s & Colitis Foundation for IBD therapies

Evotec partners with Crohn’s & Colitis Foundation for I...

Jan 11, 2024

STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns

STAT+: Sanofi ends deal for a rare disease drug after F...

Dec 11, 2023